Withdrawal: "Primary prevention of sickle cell disease using preimplantation genetic testing and in vitro fertilization is cost-effective." Christina N. Cordeiro Mitchell, Apoorva Pradhan, Bhuchitra Singh, Rakhi P. Naik, Valerie L. Baker, Sophie M. Lanzkron, Mindy S. Christianson, Lydia H. Pecker

Am J Hematol. 2023 Nov;98(11):1819. doi: 10.1002/ajh.25974. Epub 2023 Aug 17.

Abstract

Christina N. Cordeiro Mitchell (2021) Primary prevention of sickle cell disease using preimplantation genetic testing and in vitro fertilization is cost-effective (https://doi.org/10.1002/ajh.25974). The above article, published online on 20 August 2020 in Wiley Online Library (wileyonlinelibrary.com) as an Accepted Article, has been withdrawn by agreement between the authors, the journal Editor in Chief, and John Wiley & Sons Ltd. The article has been withdrawn after the accepted article was posted online, the authors received independent feedback that has prompted them to review their analysis in the article to ensure that the original conclusions are accurate.

Publication types

  • Retracted Publication

MeSH terms

  • Anemia, Sickle Cell* / diagnosis
  • Anemia, Sickle Cell* / genetics
  • Cost-Benefit Analysis
  • Fertilization in Vitro
  • Genetic Testing
  • Humans
  • Primary Prevention